Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Masoprocol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R known ✓ | P08069 | 1/20 | 0.88 |
| ▸ | ALOX15 | P16050 | 8/20 | 0.88 |
| ▸ | ALOX12 | P18054 | 7/20 | 0.88 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.88 |
| ▸ | RECQL | P46063 | 3/20 | 0.88 |
| ▸ | MEN1 | O00255 | 2/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | ESR1 | P03372 | 2/20 | 0.88 |
| ▸ | TP53 | P04637 | 2/20 | 0.88 |
| ▸ | HPGD | P15428 | 2/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.88 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.88 |
| ▸ | FOS | P01100 | 2/20 | 0.88 |
| ▸ | TTR | P02766 | 2/20 | 0.88 |
| ▸ | JUN | P05412 | 2/20 | 0.88 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nordihydroguaiaretic Acid SCHEMBL13906133 | 0.94 | ALOX15 (1.00) | ALOX15ALOX12HIF1AHSD17B10KDM4E | |
| Masoprocol SCHEMBL29355090 | 0.94 | ALOX15 (1.00) | ALOX15ALOX12HIF1AHSD17B10KDM4E | |
| Nordihydroguaiaretic Acid SCHEMBL29434237 | 0.94 | ALOX15 (1.00) | ALOX15ALOX12HIF1AHSD17B10KDM4E | |
| Masoprocol SCHEMBL29350884 | 0.94 | ALOX15 (1.00) | ALOX15ALOX12HIF1AHSD17B10KDM4E | |
| Nordihydroguaiaretic Acid SCHEMBL135976 | 0.94 | ALOX15 (1.00) | ALOX15ALOX12HIF1AHSD17B10KDM4E | |
| Masoprocol SCHEMBL3818 | 0.94 | ALOX15 (1.00) | ALOX15ALOX12HIF1AHSD17B10KDM4E | |
| Nordihydroguaiaretic Acid SCHEMBL29434238 | 0.94 | ALOX15 (1.00) | ALOX15ALOX12HIF1AHSD17B10KDM4E | |
| Nordihydroguaiaretic Acid SCHEMBL28026820 | 0.92 | ALOX15 (0.88) | ALOX15ALOX12HIF1AHSD17B10KDM4E | |
| Masoprocol SCHEMBL28156467 | 0.92 | ALOX15 (0.96) | ALOX15ALOX12HIF1AHSD17B10KDM4E | |
| SCHEMBL1755356 | 0.90 | ALOX15 (0.85) | ALOX15ALOX12HIF1AHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235714-A1 | CANCER THERAPY | TRIACT THERAPEUTICS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8710104-B2 | Catecholic butanes and use thereof for cancer therapy | TRIACT THERAPEUTICS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2349235-A1 | USE OF CATECHOLIC BUTANE DERIVATIVES IN CANCER THERAPY | Triact Therapeutics, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100256232-A1 | Cancer Therapy | TRIACT THERAPEUTICS, INC. | 2010-10-07 | — | — | US | disclosed |
| WO-2010054264-A1 | USE OF CATECHOLIC BUTANE DERIVATIVES IN CANCER THERAPY | TRIACT THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235714-A1 | CANCER THERAPY | IGF1R, ERBB2, EGFR | IGF1R 1/4885ALOX15 1440/4885ALOX12 1372/4885 |
| US-20100256232-A1 | Cancer Therapy | IGF1R, ERBB2, EGFR | IGF1R 1/4885ALOX15 1440/4885ALOX12 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.